By Dan L. Burk, Special to CNN
Editor’s note: Dan L. Burk is Chancellor’s Professor of Law at University of California, Irvine. The views expressed are his own.
On June 13, the U.S. Supreme Court announced its decision in Association for Molecular Pathology v. Myriad, a closely watched case considering the patentability of human genes.
Numerous media headlines immediately after the decision’s release proclaimed that the court had found human genes to be unpatentable. But such characterizations are misleading, ignoring the court’s actual holding that some human genes – specifically, those isolated from natural sources – are unpatentable, while other versions created in the laboratory are in fact eligible for patents.
The case involved patent claims to two different types of DNA sequences. The first, dubbed genomic DNA or “gDNA” constitutes the molecule as it is extracted from human cells. The second, known as complimentary DNA or “cDNA” is created in the laboratory through a process known as reverse transcription. The question in the case was whether either or both such DNA molecules qualify as patentable subject matter.
Patents are intended to offer an incentive for investment in new technologies, by creating a legal right to exclude others from making, using, or selling the invention described in the patent. But this incentive comes at a cost: while the patent holder can charge a premium to recoup her investment in the invention, others besides the patent holder are prohibited from using the technology during the 20 year term of the patent. So patents serve simultaneously as an accelerator and as a brake on technological progress.
More from CNN: Why cancer tests cost so much
In order to ensure that the incentive accelerator effect wins out over the exclusivity brake, society is cautious in distributing patents – they are only supposed to be granted to new and significant advances in technology, which we hope will be worth the cost. Among other limits, this means that technologies already accessible, such as items that are already found available in nature, should be precluded from receiving a patent.
The Myriad decision considers how that limit applies in the cases of gDNA and cDNA. In a nearly unanimous 9-0 opinion – with only a slight quibble in concurrence by Justice Scalia, who complained that he did not fully understand the science – the justices held that the genomic DNA sequences were not different enough from those found in human cells to warrant a patent. But they equally unanimously held that the cDNA sequences created in the laboratory differed enough to constitute patentable subject matter.
This outcome was not much of a surprise. Patent experts and Supreme Court watchers expected that the court would look for a way to issue a very narrow holding. A broad holding in the Myriad case had the potential to disrupt innovation far beyond breast cancer or any other type of medical testing. DNA sequences are important not only to genetic testing, but to a wide range of other biotechnology companies, including pharmaceutical, chemical, and even agricultural firms.
The Supreme Court was unquestionably aware that an adverse ruling on DNA patents would upset the business expectations created by 30 years of such patents granted by the Patent Office. This was certainly on the minds of judges in the lower courts who cited such expectations as a reason to leave the gDNA patents intact. Additionally, a broad limitation on patenting substances found in nature has a potentially very wide effect – for example, potentially undermining the value of new drugs or treatments found in the rainforest, or at the bottom of the ocean, or in other unexplored areas.
Limiting its holding to the invalidation of gDNA patent claims, while upholding the claims to cDNA, was one way of narrowing the Myriad ruling. While the value of existing cDNA patents may be partially undermined by the new access to similar gDNAs, industries that rely on DNA patents can still protect the laboratory versions of the molecules. The ruling also explicitly excludes molecules that might infrequently and accidentally occur in nature from invalidating patents on laboratory synthesized molecules.
But what may be more surprising about the opinion are the numerous hints dropped by Justice Thomas, suggesting how researchers and future patent drafters might go a about writing an acceptable DNA patent. For example, the opinion suggests that a patent to gDNA that was drafted in terms of chemical structure might pass muster. The opinion also goes out of its way to point out that it does not invalidate process claims, or claims to applied uses of genomic DNA, nudging patent drafters toward those forms of claims for future inventions.
Such openings for future DNA patents may leave unanswered more questions than they answer, and indeed may create new questions about the scope and application patent law’s product of nature doctrine. But they also leave open the conceptual and legal space necessary for the patent system to promote future investment in industries that are dependent on this kind of innovation.
What the media missed explaining to the public, is the implications for GMO (genetically modified organisms – i.e. food crops). Will this ruling open the door to limiting existing or new patents on crop seeds? Are any of the "naturally occurring" plant DNA currently patented? Should this ruling open the gate to legislating non-human gene patenting?
I bet that chick holding up the sign hopes they find a fix for that "fat" gene soon. Hahahahahahahahaha
Do these jeans make me look fat? No those genes make you fat. Hahahahahahahahah
In honor of the Supreme Court decision I thought it would be cool to create this #patentwars inspired T-Shirt. https://teespring.com/patentdenied See if you like it...
Scalia actually said: "I join the judgment of the Court, and all of its opinion except Part I–A and some portions of the rest of the opinion going into fine details of molecular biology. I am unable to affirm those details on my own knowledge or even my own belief." The author of this article, Dan L. Burk, mistakes Scalia's scientific humility with willful ignorance and/or stupidity (the tone and word choice is abundantly clear: "quibble" and "did not fully understand the science").
Think of it as swearing an oath under pains of perjury. Are you be willing to affirm that the science is 100% correct and will not be disproven in the future? That it might perhaps be more complicated, perhaps?
Good point Anon. It exasperates me to see lazy and arrogant simplifying of a nuance. Clearly it is done, at least in this case, to belittle the judge. One sees such mischief by many, many reporters and 'experts' – simply because they can.
I don't think Scalia's language demonstrates humility. Scalia makes it clear he does not BELIEVE in fundamental principles of molecular biology. (the tone and word choice are abundantly clear: "my OWN BELIEF"). It's one thing to say you don't understand science, but to say you don't even "believe" in fundamental principles of molecular biology is another thing. Part I-A is not even controversial or "complicated": one look reveals principles of molecular biology that can be found in any high school textbook since the 1950's (cell reproduction, transcription, etc.)
Scalia's own faith does not even warrant his reservations. The Catholic Church recognizes and accepts science as a source of knowledge on such matters as evolution, biology, etc. If Scalia is refusing to acknowledge such knowledge on the basis of his beliefs, he misunderstands his own beliefs.
Thanks for your great information, the contents are quiet interesting.I will be waiting for your next post.
Mobile Accessories Online
Check out hot deals on our online store "hotdealsunlimited.com" for mobile case and covers, mobile pouch, ipad leather case, tablet pc case etc...,..,.
The Global Public Square is where you can make sense of the world every day with insights and explanations from CNN's Fareed Zakaria, leading journalists at CNN, and other international thinkers. Join GPS editor Jason Miks and get informed about global issues, exposed to unique stories, and engaged with diverse and original perspectives.
Every week we bring you in-depth interviews with world leaders, newsmakers and analysts who break down the world's toughest problems.
CNN U.S.: Sundays 10 a.m. & 1 p.m ET | CNN International: Find local times
Buy the GPS mug | Books| Transcripts | Audio
Connect on Facebook | Twitter | GPS@cnn.com
Buy past episodes on iTunes! | Download the audio podcast
Check out all of Fareed's Washington Post columns here:
Obama as a foreign policy president?
Why Snowden should stand trial in U.S.
Hillary Clinton's truly hard choice
China's trapped transition
Obama should rethink Syria strategy
Enter your email address to follow this blog and receive notifications of new posts by email.
RSS - Posts
Get every new post delivered to your Inbox.
Join 4,864 other followers